top of page
Vaccine development infographics - Mimi Guo.png

This project is aimed to engage public interest in vaccine development. The poster takes Gardasil – an HPV vaccine – as an example, to explain each crucial and necessary stage it takes, for a novel vaccine to be approved for use in the market. To see how long it takes to make a vaccine, the infographic also includes a comprehensive development timeline for each vaccine preventable disease.

Faculty advisor

Dr. Jodie Jenkinson

Medium/Software

Adobe Illustrator

Final presentation format

27 x 36 inches wall poster

Primary audience

Lay audience

Work Process

1. Ideation

I always wanted to design a beautiful graphic for people to get to know the drug development process. During my co-op time in a pharmaceutical company, I realize that this is a very streamlined but complicated process that few people know of. It's important for the public to understand what effort goes into developing vaccines and medications so that people can trust the product. A clear and engaging visual is needed to help people digest all the information related. 

topic.PNG

Reference

  1. Shi, L., Sings, H. L., Bryan, J. T., Wang, B., Wang, Y., Mach, H., Kosinski, M., Washabaugh, M. W., Sitrin, R. Barr, E. (2006). GARDASIL®: Prophylactic Human Papillomavirus Vaccine Development – From Bench Top to Bed‐side. Clinical Pharmacology & Therapeutics, 81(2), 259-264. doi:10.1038/sj.clpt.6100055

  2. Cunningham, A. L., Garcon, N., Leo, O., Friedland, L. R., Strugnell, R., Laupèze, B., Doherty, M., & Stern, P. (2016). Vaccine development: From concept to early clinical testing. Vaccine, 34(52), 6655-6664. https://doi.org/10.1016/j.vaccine.2016.10.016. 

  3. Callaway, E., (2020, April 28). The race for coronavirus vaccines: a graphical guide. Nature News Feature. https://www.nature.com/articles/d41586-020-01221-y

  4. Siddiqui, M. A. A., & Perry, C. M. (2006). Human Papillomavirus Quadrivalent (types 6, 11, 16, 18) Recombinant Vaccine (Gardasil®). Drugs, 66(9), 1263-1271. https://doi.org/10.2165/00003495-200666090-00008

  5. Villa, L. L., Costa, R. L., & Petta, C. A. et al. (2005). Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. The Lancet Oncology, 6(5), 271-278. https://doi.org/10.1016/S1470-2045(05)70101-7. 

  6. Buckland, B. C. (2005). The process development challenge for a new vaccine. Nature Medicine, 11, S16-S19. https://doi.org/10.1038/nm1218

  7. Block, S. L., Brown, D. R., & Chatterjee, A. et al. (2010). Clinical Trial and Post-Licensure Safety Profile of a Prophylactic Human Papillomavirus (Types 6, 11, 16, and 18) L1 Virus-Like Particle Vaccine. The Pediatric Infectious Disease Journal, 29(2), 95-101. doi: 10.1097/INF.0b013e3181b77906.

  8. Serdobova, I. & Kieny, MP. (2011). Assembling a Global Vaccine Development Pipeline for Infectious Diseases in the Developing World. American Journal of Public Health, 96, 1554-1559. https://doi.org/10.2105/AJPH.2005.074583

bottom of page